Patent: 10,744,204
✉ Email this page to a colleague
Summary for Patent: 10,744,204
| Title: | Conjugated compounds comprising cysteine-engineered antibodies |
| Abstract: | This disclosure provides conjugate compounds comprising antibodies and fragments thereof engineered with one or more reactive cysteine residues and more specifically to conjugate compounds with therapeutic or diagnostic applications. The conjugate compounds comprise cysteine-engineered antibodies or fragments thereof conjugated, for example, with chemotherapeutic drugs, toxins, and detection labels such as radionuclides or fluorophores. The disclosure also provides methods of using the disclosed conjugate compounds for in vitro, in situ, ex vivo, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. |
| Inventor(s): | Changshou Gao, Godfrey RAINEY, Cuihua GAO |
| Assignee: | MedImmune LLC |
| Application Number: | US15/302,036 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,744,204
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Sanofi-aventis U.s. Llc | ADLYXIN | lixisenatide | Injection | 208471 | July 27, 2016 | 10,744,204 | 2035-04-10 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 10,744,204
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2015157595 | ⤷ Get Started Free |
| United States of America | 2021069341 | ⤷ Get Started Free |
| United States of America | 2018169255 | ⤷ Get Started Free |
| Turkey | 201903526 | ⤷ Get Started Free |
| San Marino | T201900160 | ⤷ Get Started Free |
| >Country | >Patent Number | >Estimated Expiration |
